Aradhana Sarin

Chief Financial Officer & Executive Director, AstraZeneca

Search every verified Aradhana Sarin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Aradhana Sarin, Chief Financial Officer and Executive Director of AstraZeneca, appeared on NYSE Live on June 5, 2026, to discuss the company's revenue growth goals. She stated that the company aims to double its revenues in five to six years and is investing approximately $15 billion annually in research and development, which she said is intended to drive growth beyond 2030. Sarin attributed the company's recent success to the work of its nearly 95,000 employees and described the current period as "the best time for this industry" due to rapid scientific advancements in technologies such as antibody drug conjugates and bispecifics. Sarin also addressed the company's listing of ordinary shares on the New York Stock Exchange, noting that about 45% of AstraZeneca's shareholders are based in the United States and that the move was intended to reduce friction for those investors and allow retail participation. She highlighted that the company has received eight FDA approvals in 2026 and has 20 new molecular entities in its pipeline, with 10 already approved. Sarin mentioned the recent U.S. launch of a hypertension medication, which she described as beneficial for 7 million people.